Articles

Increasing incidence of dementia in the oldest old: evidence and implications

The oldest old are the fastest growing segment of the US population but accurate estimates of the incidence of dementia in this age group have been elusive. Corrada and colleagues present data on the 5-year ag...

Authors: Bryan D James and Julie A Schneider

Con: Can neuropathology really confirm the exact diagnosis?

Clinical diagnostic accuracy using revised consensus criteria and newly developed biomarkers ranges from 65 to 96% for Alzheimer's disease (AD), with a diagnostic specificity versus other dementias of 23 to 88...

Authors: Kurt A Jellinger

Pro: Can neuropathology really confirm the exact diagnosis?

Recent advances in the clinical diagnostic instruments for diagnosing Alzheimer's disease (AD) and in neuroimaging may cast doubt in the minds of some practitioners about the continued need for neuropathology ...

Authors: Margaret M Esiri

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?

Drug candidates targeting amyloid-β (Aβ) pathology in Alzheimer's disease are in different phases of clinical trials. These treatments will probably be most effective in the earlier stages of the disease, befo...

Authors: Kaj Blennow and Henrik Zetterberg

Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander?

The strongest known risk factors for late-onset Alzheimer disease (LOAD) remain a positive family history and the APOE ε4 allele. van Exel and colleagues used these known risk factors to identify high- and low-ri...

Authors: Zaldy S Tan and Sudha Seshadri

Can novel therapeutics halt the amyloid cascade?

The amyloid hypothesis provides a basis for the development of new therapeutic strategies in Alzheimer's disease. Two large trials have recently been published. The first is a phase 2 study of passive immunoth...

Authors: Niels D Prins, Pieter Jelle Visser and Philip Scheltens

Pinpointing key mechanisms in Alzheimer's disease development

van Exel and colleagues present an elegant study testing relationships between vascular and inflammatory traits and the risk of Alzheimer's disease (AD) development. They compared middle-aged offspring of AD c...

Authors: Julie Williams

A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease

LY450139 (semagacestat) inhibits γ-secretase, a key enzyme for generation of amyloid β (Aβ), the peptide deposited in plaques in Alzheimer disease (AD). Previous data have shown that LY450139 lowers plasma Aβ,...

Authors: Erik Portelius, Robert A Dean, Mikael K Gustavsson, Ulf Andreasson, Henrik Zetterberg, Eric Siemers and Kaj Blennow

Genetics of Alzheimer disease in the pre- and post-GWAS era

Since the 1990s, the genetics of Alzheimer disease (AD) has been an active area of research. The identification of deterministic mutations in the APP, PSEN1, and PSEN2 genes responsible for early-onset autosomal ...

Authors: Nilüfer Ertekin-Taner

Predicting progression of Alzheimer's disease

Clinicians need to predict prognosis of Alzheimer's disease (AD), and researchers need models of progression to develop biomarkers and clinical trials designs. We tested a calculated initial progression rate t...

Authors: Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby and Wenyaw Chan

Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy

Evidence for the involvement of inflammatory processes in the pathogenesis of Alzheimer's disease (AD) has been documented for a long time. However, the inflammation hypothesis in relation to AD pathology has ...

Authors: Elina Zotova, James AR Nicoll, Raj Kalaria, Clive Holmes and Delphine Boche

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

There are no empiric data to support guidelines for duration of therapy with antidementia drugs. This study examined whether persistent use of antidementia drugs slows clinical progression of Alzheimer disease...

Authors: Susan D Rountree, Wenyaw Chan, Valory N Pavlik, Eveleen J Darby, Samina Siddiqui and Rachelle S Doody

Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease

Amyloid is deposited in the walls of arteries and capillaries as cerebral amyloid angiopathy (CAA) in the brains of older individuals and of those with Alzheimer disease (AD). CAA in AD reflects an age-related...

Authors: Roy O Weller, Stephen D Preston, Malavika Subash and Roxana O Carare

Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases

Alzheimer's disease (AD) and a host of other neurodegenerative central nervous system (CNS) proteinopathies are characterized by the accumulation of misfolded protein aggregates. Simplistically, these aggregat...

Authors: Todd E Golde and Victor M Miller

Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND)

Identifying the causes of dementia is important in the search for effective preventative and treatment strategies. The concept of mild cognitive impairment (MCI), as prodromal dementia, has been useful but rem...

Authors: Blossom CM Stephan, Fiona E Matthews, Kay-Tee Khaw, Carole Dufouil and Carol Brayne

Angiotensins and Alzheimer's disease: a bench to bedside overview

The pathology of Alzheimer's disease (AD) features amyloid β peptide deposition, intracellular neurofibrillary tangles and deficits in the cholinergic pathway. Abnormal blood pressure is recognised as a risk f...

Authors: Patrick G Kehoe

Alzheimer's disease therapeutic research: the path forward

The field of Alzheimer's disease therapeutic research seems poised to bring to clinic the next generation of treatments, moving beyond symptomatic benefits to modification of the underlying neurobiology of the...

Authors: Paul S Aisen

Welcome to Alzheimer's Research & Therapy

Authors: Ann Donnelly, Doug Galasko, Todd Golde, Frances Mulvany and Gordon Wilcock